Zhejiang Sunflower Great Health Co., Ltd. (SHE:300111)
3.200
-0.160 (-4.76%)
Nov 13, 2026, 3:04 PM CST
SHE:300111 Revenue
Zhejiang Sunflower Great Health had revenue of 62.94M CNY in the quarter ending September 30, 2026, with 14.22% growth. This brings the company's total for the last twelve months to 243.52M, down -19.61% year-over-year. In the year 2025, Zhejiang Sunflower Great Health had annual revenue of 271.53M, down -17.81%. That makes Zhejiang Sunflower Great Health the 30,125th largest company in the world by revenue and 4,957th in China.
Revenue (ttm)
243.52M
Revenue Growth
-19.61%
P/S Ratio
17.13
Revenue / Employee
803.70K
Employees
303
Market Cap
4.12B
Revenue by Geography
- China 176.08M 64.8%
- Foreign 95.45M 35.2%
Fiscal year ended Dec 31, 2025 See the full SHE:300111 breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 271.53M | -58.83M | -17.81% |
| Dec 31, 2024 | 330.37M | -8.05M | -2.38% |
| Dec 31, 2023 | 338.42M | 2.56M | 0.76% |
| Jan 1, 2023 | 335.86M | 38.57M | 12.97% |
| Jan 1, 2022 | 297.29M | 10.33M | 3.60% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Jianmin Pharmaceutical Group | 3.12B |
| Luoxin Pharmaceuticals Group Stock | 2.23B |
| Yabao Pharmaceutical Group | 2.19B |
| Hunan Fangsheng Pharmaceutical | 1.88B |
| Fuan Pharmaceutical (Group) | 1.65B |
| Guizhou Sanli Pharmaceutical Co.,Ltd | 1.64B |
| Shandong Wit Dyne Health | 1.51B |
| Beijing Beilu Pharmaceutical | 1.39B |